AstraZeneca Receives “Hold” Rating from Deutsche Bank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities researchers at Deutsche Bank in a research report issued on Thursday, American Banking News reports. They currently have a GBX 3,600 ($59.05) price target on the stock. Deutsche Bank’s target price indicates a potential upside of 0.73% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Nordea Equity Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a GBX 4,218.14 ($69.18) price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of AstraZeneca from GBX 3,200 ($52.48) to GBX 3,700 ($60.69) in a research note to investors on Monday. They now have a “neutral” rating on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Friday, December 20th. Thirteen equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have issued a buy rating to the company. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 3,125.31 ($51.26).
AstraZeneca (LON:AZN) traded up 0.69% on Thursday, hitting GBX 3574.0002. The stock had a trading volume of 2,301,887 shares. AstraZeneca has a one year low of GBX 2895.00 and a one year high of GBX 3669.50. The stock has a 50-day moving average of GBX 3505.82 and a 200-day moving average of GBX 3293.11. The company’s market cap is £44.782 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.